The Various Clinical Research Monitoring Visits Deconstructed

The session opens by welcoming attendees to the November webinar, also available on YouTube and as a podcast. The speaker notes the record number of registrants, indicating strong interest in the topic. The primary goal is to deconstruct common monitoring visits, particularly beneficial for new research sites, coordinators, PIs, and those aspiring to enter the industry. The discussion will cover various monitoring visit types, offering insights for both CRAs and research sites. The four main types of visits are introduced: Site Selection (SSV), Site Initiation (SIV), Interim Monitoring (IMV), and Close-out (COV). Booster visits and pre-audit visits are acknowledged but not covered in depth.

The Site Selection Visit (SSV), also known by acronyms like PSSV or PSSB, involves assessing a site's capabilities. If a site has no prior experience with a sponsor or CRO, an in-person SSV is typically conducted. Key objectives include evaluating patient recruitment potential (the most crucial aspect), the site's technical capabilities, and the PI's experience with the indication. Enrollment projections and staff experience are also vital. From a CRA's perspective, the primary task during an SSV is to gather and document extensive information for a detailed report, which is often the longest a CRA writes. The speaker shares a humorous anecdote about a monitor asking the site to fill out portions of their report. It's emphasized that once a sponsor sends a CRA for an SSV, the study is 'yours to lose' – meaning the site is highly likely to be selected unless significant discrepancies or issues arise during the visit.

The Site Initiation Visit (SIV) occurs after a site has been selected. Before the SIV, sites are expected to complete regulatory documents and budget negotiations. During the SIV, the CRA ensures the site is ready to begin the study. Key activities include protocol training for the PI and staff, verifying access to EDC (Electronic Data Capture), IWRS, lab, and ECG systems, confirming IRB approval, and ensuring all necessary study supplies (lab kits, study drug, source documents) are available. This visit formally activates the site, allowing patient screening to commence. The speaker notes that SIVs can be challenging for PIs due to the time commitment for training, but they represent the start of the clinical work. The importance of completing delegation of duties and training logs before the CRA's arrival is highlighted.

Interim Monitoring Visits (IMVs) constitute the majority of monitoring visits throughout a study. Each IMV can be different, even for the same study, depending on the specific issues or focus areas at each site. Examples include following up on SAEs, deviations, temperature excursions, enrollment challenges, or regulatory compliance. CRAs typically follow their monitoring report as a guide, often starting with informed consent review and regulatory matters. A key piece of advice for sites is to proactively address and update the CRA on previous action items, which significantly streamlines the visit. From a CRA's perspective, a crucial role during IMVs is ensuring patient safety, particularly that only appropriate subjects are randomized and meet inclusion/exclusion criteria. The complexity of studies often leads to missed details, making the CRA's oversight critical for preventing issues that could lead to FDA scrutiny.

The Close-out Visit (COV) marks the conclusion of a site's participation in a study. The main objective is site deactivation. During a COV, the CRA ensures all EDC casebooks are electronically signed by the PI, all queries are answered, and data reconciliation is complete. The IRB must be notified of the site's closure. Crucially, IP (Investigational Product) reconciliation is performed to ensure all IP is accounted for and either destroyed or returned to the sponsor. Similarly, lab kits and any rented equipment must be accounted for and handled appropriately. The PI is also responsible for signing and dating all SUSAR (Suspected Unexpected Serious Adverse Reactions) reports and updating the delegation of authorities log with end dates for all staff. All types of visits (SSV, SIV, IMV, COV) follow a standard communication process: a confirmation letter before the visit, a monitoring report submitted internally to the CRO (not the site), and a follow-up letter to the site with action items.

The session concludes with a Q&A segment. Questions arise regarding charging sponsors for IP destruction and other lesser-known items. The speaker explains that sponsors often have SOPs dictating what they will pay for, but sites can negotiate. It's noted that being paid for monitoring visits themselves is sometimes possible. The hosts also promote their services, including monthly consulting, site owner academy, and CRA academy, highlighting their value in business development, budget negotiation, SOP assistance, and clinical operations support. Attendees are encouraged to reach out with further questions and to view the slides on YouTube if listening via podcast.